Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents
F. Zhang, J. Jenkins, R. V. H. de Carvalho, S. Nakandakari-Higa, T. Chen, M. E. Abernathy, E. Nyakatura, D. Andrew, I. V. Lebedeva, I. C. Lorenz, H.- H. Hoffmann, C. M. Rice, G. D. Victora, C. O. Barnes, T. Hatziioannou, P. D. Bieniasz
The paper develops human monoclonal antibodies targeting the ACE2 receptor to block infection by SARS-CoV-2 and related sarbecoviruses, showing broad efficacy against variants and no adverse effects on ACE2 function.
bioRxiv · Aug 24, 2022 · PreprintMicrobiology